Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIANO: SHR9146 Combinations in Solid Tumors
NCT03491631Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Nov 2018
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HTI-1090 in solid tumor (advanced stage) (2 arms), sponsored by Hengrui. Primary endpoints: Dose-Limiting Toxicity at 28 days and Maximum Tolerated Dose at 28 days. Status: unknown.
02
Drugs
HTI-1090
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03491631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03491631.